Oncologist in West Hills, CA: Lung, Colon, Breast, Prostate, and Myeloma Care

Yes. Some lung cancers cause few noticeable symptoms early, while others may cause a persistent or worsening cough, shortness of breath, chest pain, coughing up blood, hoarseness, fatigue, or unexplained weight loss. These symptoms can also have causes other than cancer, so persistent or concerning symptoms should be evaluated rather than used to diagnose lung cancer on their own.

There is no single progression timeline for lung cancer. Small cell lung cancer tends to grow and spread quickly, while non-small cell lung cancers vary considerably in their behavior. The cancer subtype, stage, molecular features, previous treatment, and individual patient all affect how the disease behaves. Imaging, pathology, and staging information are needed to evaluate a specific case.

Lung cancer may spread to nearby lymph nodes or distant sites such as the brain, bones, liver, or adrenal glands, but the pattern is not the same for every patient. Imaging, pathology, and other staging tests are used to determine whether cancer has spread and to guide treatment planning.

Colon cancer may cause changes in bowel habits, blood in the stool, abdominal discomfort, fatigue, or unexplained weight loss, although some people have no symptoms early in the disease. These symptoms can also have causes other than cancer. Screening can identify some colorectal cancers or precancerous polyps before symptoms appear, while persistent or concerning symptoms should be evaluated by a health care professional.

Colon cancer begins in the inner lining of the colon. Some colon cancers develop from abnormal growths called polyps, although most polyps do not become cancerous. Finding and removing certain precancerous polyps during recommended colorectal cancer screening can help prevent cancer from developing.

Doctors evaluate possible breast cancer spread using the patient’s symptoms, examination, imaging, laboratory findings, and biopsy when needed. Depending on the situation, imaging may examine the bones, lungs, liver, brain, or other areas. A biopsy of a suspicious site can sometimes confirm that a distant lesion is metastatic breast cancer. The appropriate tests depend on the original cancer, symptoms, and previous treatment.

Breast cancer outcomes vary according to stage, tumor biology, hormone-receptor and HER2 status, response to treatment, overall health, and other individual factors. Many people with early-stage breast cancer complete treatment and live for many years, but no individual prognosis can be predicted from general statistics alone. Follow-up care remains important for monitoring recurrence, managing treatment effects, and supporting long-term health.

Prostate cancer starts in the prostate gland and, if it advances, most commonly spreads to nearby lymph nodes and the bones, and less often to organs such as the liver or lungs. Many prostate cancers grow slowly and stay localized. Staging determines how far it has progressed and what treatment fits best.

Changes that may lead an oncology team to investigate prostate cancer progression can include new or worsening bone pain, urinary changes, weakness, weight loss, or other persistent symptoms, depending on where the disease is located. A rising PSA is not a symptom but can be an important monitoring finding. PSA trends, imaging, examination, and other tests are interpreted together to assess whether the cancer is changing.

Multiple myeloma is assessed using blood tests, bone marrow findings, imaging, and disease-risk features. Staging considers factors such as beta-2 microglobulin, albumin, LDH, and certain chromosomal abnormalities. Symptoms such as bone pain, anemia-related fatigue, kidney problems, or recurrent infections may also affect evaluation and treatment planning, but symptoms alone do not determine the stage.

Breast cancer treatment is based on the type and stage and often combines more than one approach, including surgery, radiation, chemotherapy, hormone therapy, and targeted or immune-based therapies. Most early-stage cases involve some form of surgery, with additional treatment before or after as needed. The plan is personalized to each patient’s diagnosis and health.

Prostate cancer treatment depends on the severity of the disease and may include active monitoring for slow-growing cases, surgery, radiation, androgen-deprivation (hormone) therapy, chemotherapy, or in some situations immunotherapy. The right choice balances controlling cancer with protecting quality of life. Your oncologist tailors the approach to your specific case.

Multiple myeloma treatment is individualized according to disease features, symptoms, previous therapy, overall health, and transplant eligibility. Treatment may include combinations of targeted drugs, immunotherapies, corticosteroids, chemotherapy, supportive treatments, and, for selected patients, hematopoietic stem cell transplantation, often using the patient’s own stem cells. Radiation may be used for selected bone lesions or symptoms. The treatment plan and sequence can change over time according to response and disease status.

Immunotherapy includes treatments that help the immune system recognize, target, or control cancer. Examples include immune checkpoint inhibitors and other immune-based therapies. Whether immunotherapy is appropriate depends on the cancer type, stage, biomarkers, previous treatment, overall health, and the specific drug being considered. It may be used alone or with chemotherapy, targeted therapy, or other treatment in selected cancers.

Targeted therapy uses drugs or other treatments designed to act on specific molecules, proteins, pathways, or genetic changes involved in cancer growth. Biomarker or molecular testing may help determine whether a tumor has a target for an available therapy. Targeted treatments can still cause significant side effects, so the expected benefits and risks depend on the specific drug, cancer, and individual patient.